Terminated PHASE4 INTERVENTIONAL 2-arm NCT00574041

How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose (TODAY)

An Open-Label Study to Examine the Difference in Tolerability Associated With Titration Of Dose on Initiation of Avonex therapY (TODAY)

Sponsor: Biogen

Conditions Relapsing Remitting Multiple Sclerosis

Interventions Interferon beta-1a

Updated 6 times since 2017 Last updated: Sep 2, 2008 Started: Jun 30, 2007 Primary completion: Feb 29, 2008 Completion: Feb 29, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Terminated due to poor recruitment

Other terminated trials from Biogen

See all terminations from Biogen

Other Relapsing Remitting Multiple Sclerosis trials with similar outcome

Browse all Relapsing Remitting Multiple Sclerosis trials

This PHASE4 trial investigates Relapsing Remitting Multiple Sclerosis and is currently terminated or withdrawn. Biogen leads this study, which shows 6 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE4
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE4
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE4
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE4
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE4

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Terminated PHASE4

First recorded

Jun 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Biogen

Data source: Biogen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Malvern, Australia